Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.


Rufomycin is a class of cyclic peptides that includes various structurally characterized isolates and semisynthetic derivatives. These compounds are known by synonymous names, including ilamycin, and have been the subject of studies aiming to clarify their structures and nomenclature.

One of the significant findings about rufomycin is its potential as a treatment for Mycobacterium tuberculosis infections. Rufomycin, particularly Rufomycin I (RUFI), has been found to have bactericidal properties against M. tuberculosis by inhibiting a target known as ClpC1. This inhibition affects the protein degradation pathway within the bacteria, which is crucial for their survival. Rufomycin I has shown effectiveness against various strains of M. tuberculosis, including multidrug-resistant and extensively drug-resistant strains.

The activity of Rufomycin I against Mycobacterium tuberculosis has been demonstrated to be both time and concentration-dependent, making it a potent and selective lead compound for this pathogen, as well as for Mycobacterium abscessus.

Research on rufomycin has also delved into its molecular structure and the relationship between its structural variations and antimycobacterial activity. The detailed understanding of these relationships can aid in the development of rufomycin as a therapeutic agent.

More information can be found in the references within this website.